

Title (en)

TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME

Title (de)

TREPROSTINILDERIVATVERBINDUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON

Title (fr)

COMPOSÉS DE DÉRIVÉS DE TRÉPROSTINIL ET LEURS PROCÉDÉS D'UTILISATION

Publication

EP 3169660 A1 20170524 (EN)

Application

EP 14748380 A 20140716

Priority

US 2014046920 W 20140716

Abstract (en)

[origin: WO2016010538A1] Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

IPC 8 full level

C07C 69/712 (2006.01); **A61K 31/165** (2006.01); **A61K 31/192** (2006.01); **A61K 31/215** (2006.01); **A61K 31/341** (2006.01); **A61P 9/12** (2006.01); **C07C 59/72** (2006.01); **C07D 235/06** (2006.01); **C07D 257/06** (2006.01); **C07D 263/22** (2006.01); **C07D 295/088** (2006.01); **C07D 307/20** (2006.01); **C07D 453/02** (2006.01); **C07D 493/00** (2006.01)

CPC (source: EP)

A61P 7/02 (2017.12); **A61P 7/10** (2017.12); **A61P 9/00** (2017.12); **A61P 9/12** (2017.12); **A61P 11/00** (2017.12); **A61P 43/00** (2017.12); **C07C 59/72** (2013.01); **C07C 69/712** (2013.01); **C07C 69/74** (2013.01); **C07C 69/96** (2013.01); **C07D 211/60** (2013.01); **C07D 257/06** (2013.01); **C07D 263/26** (2013.01); **C07D 265/30** (2013.01); **C07D 295/145** (2013.01); **C07D 317/24** (2013.01); **C07D 321/00** (2013.01); **C07D 323/00** (2013.01); **C07D 453/02** (2013.01); **C07C 235/20** (2013.01); **C07C 2601/02** (2017.04); **C07C 2601/08** (2017.04); **C07C 2601/14** (2017.04); **C07C 2602/42** (2017.04); **C07C 2603/14** (2017.04)

Citation (search report)

See references of WO 2016010538A1

Citation (examination)

- DUPUIS J ET AL: "Endothelin receptor antagonists in pulmonary arterial hypertension", EUROPEAN RESPIRATORY JOURNAL, EUROPEAN RESPIRATORY SOCIETY, GB, vol. 31, no. 2, 31 January 2008 (2008-01-31), pages 407 - 415, XP009514539, ISSN: 0903-1936, DOI: 10.1183/09031936.00078207
- BUCKLEY M S ET AL: "Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy", DRUG, HEALTHCARE AND PATIENT SAFETY, DOVE MEDICAL PRESS LTD.(DOVEPRESS), GB, vol. 2, 1 January 2010 (2010-01-01), pages 151 - 161, XP002757935, ISSN: 1179-1365, [retrieved on 20100920], DOI: 10.2147/DHPS.S6215

Cited by

US11958822B2; US11339139B2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2016010538 A1 20160121; EP 3169660 A1 20170524; EP 3828160 A1 20210602; JP 2017522304 A 20170810; JP 6561109 B2 20190814

DOCDB simple family (application)

US 2014046920 W 20140716; EP 14748380 A 20140716; EP 20202064 A 20140716; JP 2017500911 A 20140716